Disease: HER2-negative breast cancer ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 Biomarker disease BEFREE <i>ERBB</i> gene family mutations, which are present in 7% of our HER2+ breast cancer cohort, may have the potential to alter cellular behaviour and the efficacy of HER- and PI3K-inhibition. 30023006 2018
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 AlteredExpression disease BEFREE We, therefore, aimed to find a better read-out of activation of the PI3K and MAPK pathways in ER+/HER2- breast cancer. 30287915 2018
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 Biomarker disease BEFREE Combination therapies with phosphoinositide 3-kinase (PI3K) inhibitors and trastuzumab (anti-human epidermal growth factor receptor [HER]2/neu antibody) are effective against HER2+ breast cancer. 29721370 2018
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 Biomarker disease BEFREE This review focuses on the recent reports of the essential role of PI3K/Akt/mTOR and CDK4/6/RB pathways in ER+ HER2- breast cancer. 29086897 2018
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 Biomarker disease BEFREE The Neoadjuvant PI3K inhibition in HER2 OverExpressing Breast cancEr (NeoPHOEBE) trial evaluated the efficacy and safety of buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus trastuzumab and paclitaxel as neoadjuvant treatment for human epidermal growth factor receptor-2 positive (HER2+) breast cancer. 28923573 2017
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 Biomarker disease BEFREE Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. 29020035 2017
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 AlteredExpression disease BEFREE Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. 24451154 2014
CUI: C4733095
Disease: HER2-negative breast cancer
HER2-negative breast cancer 		0.080 Biomarker disease BEFREE Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. 22737248 2012